Article

COA Releases Statement on Prescription Drug Pricing Reduction Act

On behalf of the Community Oncology Alliance (COA), Ted Okon, executive director of COA, has released a statement regarding the Prescription Drug Pricing Reduction Act.

On behalf of the Community Oncology Alliance (COA), Ted Okon, executive director of COA, has released a statement regarding the Prescription Drug Pricing Reduction Act. While COA supports certain provisions in the package, including encouraging a healthy and competitive biosimilars market, transparency around pharmacy benefit managers, and changes to grandfathered site-neutral payments for hospitals, there are some provisions COA is opposed to. For example: the proposal to include support from patient assistance programs in the calculation of Average Sales Price, which is the basis for Medicare Part B drug reimbursement.

According to Okon, the provision would lead to drug manufacturers to reduce or eliminate programs. Read the full press release.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Merrill H. Stewart, MD
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Hamlet Gasoyan, PhD
Dr Matthew Matasar
Dr Marina Kremskayana
Dr Sundar Jagannath
David Awad, PharmD, BCOP
Andrew Kuykendall, MD, Moffitt Cancer Center
Merrill H. Stewart, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo